MCID: ENT011
MIFTS: 51

Enterocolitis

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Enterocolitis

MalaCards integrated aliases for Enterocolitis:

Name: Enterocolitis 56 29 54 17 71

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
enterocolitis:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 226150
ICD10 32 A04.7
MedGen 41 C0014356
UMLS 71 C0014356

Summaries for Enterocolitis

MalaCards based summary : Enterocolitis is related to histoplasmosis and neisseria meningitidis infection. An important gene associated with Enterocolitis is NLRC4 (NLR Family CARD Domain Containing 4), and among its related pathways/superpathways are Innate Immune System and Shigellosis. The drugs Ceftriaxone and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and heart, and related phenotypes are hematochezia and abdominal distention

Wikipedia : 74 Enterocolitis is an inflammation of the digestive tract, involving enteritis of the small intestine and... more...

More information from OMIM: 226150

Related Diseases for Enterocolitis

Diseases related to Enterocolitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 617)
# Related Disease Score Top Affiliating Genes
1 histoplasmosis 29.8 CFH C3
2 neisseria meningitidis infection 29.6 TLR4 CD46 C3
3 complement component 2 deficiency 29.6 CFH CFB
4 meningitis 29.5 TLR4 CFI CD46 C3
5 severe pre-eclampsia 29.4 TLR4 CFH CFB C3
6 diarrhea 29.3 TLR4 THBD CFI CFH CFB CD46
7 kidney disease 29.1 THBD CFHR5 CFH C3
8 hemolytic uremic syndrome, atypical 1 28.8 THBD CFI CFHR5 CFHR3 CFHR1 CFH
9 systemic lupus erythematosus 27.3 TLR4 THBD CFI CFHR5 CFH CFB
10 hemolytic-uremic syndrome 27.1 THBD CFI CFHR5 CFHR3 CFHR1 CFH
11 thrombocytopenia 27.1 TLR4 THBD CFI CFHR5 CFHR3 CFHR1
12 hemolytic anemia 26.9 THBD CFI CFHR5 CFHR3 CFHR1 CFH
13 perinatal necrotizing enterocolitis 12.9
14 autoinflammation with infantile enterocolitis 12.8
15 mastocytic enterocolitis 12.6
16 clostridium difficile colitis 11.9
17 short bowel syndrome 11.7
18 hirschsprung disease 1 11.6
19 inflammatory bowel disease 11.5
20 patent ductus arteriosus 1 11.5
21 hypoganglionosis 11.5
22 5-oxoprolinase deficiency 11.1
23 pigmentary disorder, reticulate, with systemic manifestations, x-linked 11.1
24 hemolytic uremic syndrome, atypical 2 11.1
25 hemolytic uremic syndrome, atypical 3 11.1
26 hemolytic uremic syndrome, atypical 4 11.1
27 hemolytic uremic syndrome, atypical 5 11.1
28 hemolytic uremic syndrome, atypical 6 11.1
29 intestinal perforation 10.7
30 neutropenia 10.6
31 food allergy 10.6
32 peritonitis 10.6
33 crohn's disease 10.5
34 colitis 10.5
35 intestinal disease 10.5
36 ileus 10.5
37 gastroenteritis 10.4
38 intestinal obstruction 10.4
39 overgrowth syndrome 10.4
40 ulcerative colitis 10.4
41 acute leukemia 10.4
42 appendicitis 10.4
43 chorioamnionitis 10.3
44 metabolic acidosis 10.3
45 dysentery 10.3
46 leukemia 10.3
47 vasculitis 10.3
48 megacolon 10.3
49 heart disease 10.3
50 toxic shock syndrome 10.3

Graphical network of the top 20 diseases related to Enterocolitis:



Diseases related to Enterocolitis

Symptoms & Phenotypes for Enterocolitis

Human phenotypes related to Enterocolitis:

31
# Description HPO Frequency HPO Source Accession
1 hematochezia 31 HP:0002573
2 abdominal distention 31 HP:0003270
3 enterocolitis 31 HP:0004387
4 ulcerative colitis 31 HP:0100279

Symptoms via clinical synopsis from OMIM:

56
G I:
ulcerative colitis
bloody diarrhea
pseudomembranous enterocolitis

Abdomen:
swelling

Clinical features from OMIM:

226150

MGI Mouse Phenotypes related to Enterocolitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.43 C3 CFB CFH POLA1 THBD TLR4
2 renal/urinary system MP:0005367 9.1 C3 CFB CFH CFI THBD TLR4

Drugs & Therapeutics for Enterocolitis

Drugs for Enterocolitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
2
Adalimumab Approved Phase 4 331731-18-1 16219006
3
Teicoplanin Approved, Investigational Phase 4 61036-62-2
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Famotidine Approved Phase 4 76824-35-6 3325
8
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14 Beractant Approved Phase 4 108778-82-1
15 Poractant alfa Approved Phase 4 129069-19-8
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17 Coconut Approved Phase 4
18
Sorbitol Approved Phase 4 50-70-4 5780
19
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
20
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
22
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
24 Tocotrienol Investigational Phase 4 6829-55-6
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Immunoglobulins Phase 4
28 Antibodies Phase 4
29 Immunologic Factors Phase 4
30 Rho(D) Immune Globulin Phase 4
31 Immunoglobulins, Intravenous Phase 4
32 gamma-Globulins Phase 4
33 Amebicides Phase 4
34 Antioxidants Phase 4
35 Protective Agents Phase 4
36 Antacids Phase 4
37 Anti-Ulcer Agents Phase 4
38 Antineoplastic Agents, Hormonal Phase 4
39 Carotenoids Phase 4
40
Picolinic acid Phase 4 98-98-6 1018
41 Provitamins Phase 4
42 Iron Chelating Agents Phase 4
43 Calciferol Phase 4
44 Histamine Antagonists Phase 4
45 Histamine H2 Antagonists Phase 4
46
Histamine Phosphate Phase 4 51-74-1 65513
47 Amoxicillin-Potassium Clavulanate Combination Phase 4
48 beta-Lactamase Inhibitors Phase 4
49 Pharmaceutical Solutions Phase 4
50 Vitamins Phase 4

Interventional clinical trials:

(show top 50) (show all 521)
# Name Status NCT ID Phase Drugs
1 Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis Unknown status NCT02343562 Phase 4
2 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
3 The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants Unknown status NCT02132819 Phase 4
4 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
5 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
6 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
7 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
8 Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants Completed NCT04304807 Phase 4 Melatonin 20 mg;Traditional antibiotic treatment
9 Postmarketing Study of Probiotics Medication in Childhood Diarrhea Completed NCT00463190 Phase 4 Biothree
10 An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin Completed NCT01818141 Phase 4 Vancomycin;Fidaxomicin
11 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
12 Early Sodium Intake in Preterm Newborns; Randomized Clinical Trial Completed NCT04035564 Phase 4 Sodium < 1mEq/kg/day;Sodium 5mEq/kg/day
13 Systematic Randomized , Single Blinded, Placebo-Controlled Trial of Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
14 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Completed NCT02951702 Phase 4 Vancomycin Oral
15 Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part IV Completed NCT01604447 Phase 4
16 A Randomized Trial to Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates in Developing Countries Completed NCT01403623 Phase 4
17 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
18 A Randomized Double-Blinded Study Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome Completed NCT00201643 Phase 4 Betamethasone or Dexamethasone (2nd course of ACS);Placebo
19 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
20 Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile Completed NCT02057198 Phase 4 Fidaxomicin;Metronidazole;Vancomycin
21 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
22 Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis Recruiting NCT04003818 Phase 4 TEICOPLANIN
23 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Recruiting NCT03366584 Phase 4 Dexamethasone
24 Screening to Prophylax Against Clostridium Difficile Infection Recruiting NCT02996487 Phase 4 Vancomycin
25 A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections Recruiting NCT02692651 Phase 4 Fidaxomicin;Vancomycin
26 Historically-controlled Clinical Trial of the Efficacy and Safety of Bezlotoxumab (BEZLO) in Addition to Standard of Care (SOC) Vancomycin for the Treatment of Multi-recurrent Clostridium Difficile Infection (CDI) Recruiting NCT03880539 Phase 4 bezlotoxumab;Vancomycin Oral
27 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Recruiting NCT03667703 Phase 4 Famotidine;Placebo
28 A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Recruiting NCT04000555 Phase 4 Oral Vancomycin
29 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial Recruiting NCT02765217 Phase 4 Lactobacillus reuteri DSM 17938;Placebo;Amoxicillin-Clavulanic Acid
30 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Active, not recruiting NCT02140580 Phase 4
31 Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics Enrolling by invitation NCT03466502 Phase 4 Oral Vancomycin
32 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Not yet recruiting NCT04050488 Phase 4 Zinc Sulfate;Placebos
33 NICU Antibiotics and Outcomes Trial Not yet recruiting NCT03997266 Phase 4 Ampicillin;Gentamycin;Normal saline
34 Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Not yet recruiting NCT04138706 Phase 4 Vancomycin;Placebos
35 Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study Not yet recruiting NCT04415918 Phase 4 Bezlotoxumab Injection
36 Personalized Versus Standardized Parenteral Nutrition for Preterm Infants With a Birth Weight Greater Than 1250 Grams: a Multicenter Randomized Phase IV Clinical Trial Not yet recruiting NCT03693287 Phase 4 Standardized-parenteral nutrition (S-PN);Personalized-parenteral nutrition (P-PN)
37 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
38 Impact of Early Postnatal Sodium Supplementation on Weight Gain in Very Low Birth Weight Infants Terminated NCT01795638 Phase 4 Sodium chloride;Placebo
39 Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients Terminated NCT01972932 Phase 4
40 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
41 Effects of the Use of a Bottle and a Cup on Breast Sucking Patterns of Premature Infants: Safety and Efficacy Terminated NCT00703950 Phase 4
42 Incidence and Severity of Parenteral Nutrition Associated Cholestasis in Neonates Subjected to Major Surgery, Using Two Mixed Intravenous Lipid Emulsions Terminated NCT02633384 Phase 4
43 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
44 Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease Withdrawn NCT00304863 Phase 4 Lactobacillus GG
45 Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection Withdrawn NCT02464306 Phase 4 fidaxomicin
46 A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Withdrawn NCT02774317 Phase 4
47 A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
48 Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants Unknown status NCT01315821 Phase 3 Saccharomyces boulardii;Placebo
49 Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia Unknown status NCT03266913 Phase 3 Probiotic
50 Transplantation of Fecal Microbiota for Clostridium Difficile Infection Unknown status NCT01958463 Phase 3

Search NIH Clinical Center for Enterocolitis

Genetic Tests for Enterocolitis

Genetic tests related to Enterocolitis:

# Genetic test Affiliating Genes
1 Enterocolitis 29

Anatomical Context for Enterocolitis

MalaCards organs/tissues related to Enterocolitis:

40
Colon, Breast, Heart, Lung, Small Intestine, Liver, Brain

Publications for Enterocolitis

Articles related to Enterocolitis:

(show top 50) (show all 11646)
# Title Authors PMID Year
1
Early lethal autosomal recessive enterocolitis: report of a second family. 56 61
17204052 2007
2
A lethal autosomal recessive entero-colitis of early infancy. 56
4426135 1974
3
[Gastrointestinal abnormalities in children with autism]. 61 54
19650428 2009
4
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. 54 61
16710025 2006
5
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. 61 54
16224277 2005
6
A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice. 54 61
15632018 2005
7
Inflammatory changes secondary to postoperative complications of Hirschsprung's disease as a cause of histopathologic changes typical of intestinal neuronal dysplasia. 54 61
14966730 2004
8
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. 54 61
12826605 2003
9
Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. 54 61
7553416 1995
10
Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 61 54
7532192 1995
11
Food protein-induced enterocolitis to casein hydrolysate formulas. 54 61
8258625 1993
12
Cytotoxin-producing Klebsiella oxytoca in the preterm gut and its association with necrotizing enterocolitis. 61
32525754 2020
13
Measles in Romania - clinical and epidemiological characteristics of hospitalized measles cases during the first three years of the 2016-ongoing epidemic. 61
32507005 2020
14
A randomized controlled trial comparing the effect of fortification of human milk with an infant formula powder versus unfortified human milk on the growth of preterm very low birth weight infants. 61
30486700 2020
15
A review of the imaging manifestations of immune check point inhibitor toxicities. 61
32334270 2020
16
Reduced fetal movements at term in singleton low risk pregnancies-Is there an association with placental histopathological findings? 61
31960411 2020
17
Outcomes in preterm small versus appropriate for gestation infants after Bifidobacterium breve M-16 V supplementation. 61
30394171 2020
18
Incidence, risk factors, and outcomes of acute kidney injury in neonates after surgical procedures. 61
32232634 2020
19
Integrated analysis of a lncRNA‑mRNA network reveals a potential mechanism underlying necrotizing enterocolitis. 61
32319640 2020
20
Novel useful markers for follow-up of necrotizing enterocolitis: endocan and interleukin-33. 61
30431380 2020
21
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. 61
32553146 2020
22
Incidence of necrotising enterocolitis before and after introducing routine prophylactic Lactobacillus and Bifidobacterium probiotics. 61
31666311 2020
23
Neurodevelopmental impairment in necrotising enterocolitis survivors: systematic review and meta-analysis. 61
31801792 2020
24
Managing food protein-induced enterocolitis syndrome during the coronavirus disease 2019 pandemic: Expert recommendations. 61
32387170 2020
25
Core outcomes in neonatology: development of a core outcome set for neonatal research. 61
31732683 2020
26
The effects of latency period in PPROM cases managed expectantly. 61
32089027 2020
27
Prospective study reveals a microbiome signature that predicts the occurrence of post-operative enterocolitis in Hirschsprung disease (HSCR) patients. 61
31944159 2020
28
The Role of Human Coronavirus Infection in Pediatric Acute Gastroenteritis. 61
32433226 2020
29
The Psychosocial Impact of Food Protein-Induced Enterocolitis Syndrome. 61
32569756 2020
30
Food protein-induced enterocolitis syndrome epidemiology, diagnosis, and treatment. 61
32250971 2020
31
Chronic food protein-induced enterocolitis syndrome due to solid food. 61
32006725 2020
32
Feed intolerance in preterm neonates with antenatal reverse end diastolic flow (REDF) in umbilical artery: a retrospective cohort study. 61
30373425 2020
33
Utility of ultrasound assessment in management of pregnancies with preterm prelabor rupture of membranes. 61
31332850 2020
34
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. 61
32416073 2020
35
Higher versus lower protein intake in formula-fed low birth weight infants. 61
32573771 2020
36
Pediatric Surgery Simulation-Based Training for the General Surgery Resident. 61
32561030 2020
37
Microbiota in non-IgE-mediated food allergy. 61
32250972 2020
38
Antenatal Corticosteroids and Outcomes in Preterm Twins. 61
32459431 2020
39
Transperineal Intracath Meconiolysis and Evacuation Technique of "Distended" Bowel Evacuation for One-Stage Laparoscopic Anorectoplasty for High Anorectal Malformations in Males. 61
32216702 2020
40
Impact of Early-Onset Sepsis and Antibiotic Use on Death or Survival with Neurodevelopmental Impairment at 2 Years of Age among Extremely Preterm Infants. 61
32446491 2020
41
Chyme recycling in the management of small bowel double enterostomy in pediatric and neonatal populations: A systematic review. 61
32359729 2020
42
The symbol in the body: the un-doing of a dissociation through Embodied Active Imagination in Jungian analysis. 61
32406947 2020
43
Beneficial effects of butyrate in intestinal injury. 61
32234318 2020
44
Surgical ligation of patent ductus arteriosus in preterm neonates weighing less than 1500g: a 9-year single center experience. 61
32552772 2020
45
Prevention of Necrotizing Enterocolitis through Milk Polar Lipids Reducing Intestinal Epithelial Apoptosis. 61
32515192 2020
46
Fecal microbiota transplantation by enema reduces intestinal injury in experimental necrotizing enterocolitis. 61
32234317 2020
47
Epidemiological and genetic characterization of Clostridium butyricum cultured from neonatal cases of necrotizing enterocolitis in China. 61
32539870 2020
48
Urinary Intestinal Fatty Acid Binding Protein for Diagnosis of Necrotizing Enterocolitis. 61
32533679 2020
49
Mortality from necrotizing enterocolitis: Greater racial inequalities and differences in risk factors. 61
32278742 2020
50
The role of absolute monocyte counts in predicting severity of necrotizing enterocolitis. 61
32005918 2020

Variations for Enterocolitis

Expression for Enterocolitis

Search GEO for disease gene expression data for Enterocolitis.

Pathways for Enterocolitis

GO Terms for Enterocolitis

Cellular components related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 CFI CFHR3 CFH CFB CD46 C3
2 extracellular region GO:0005576 9.7 CFI CFHR5 CFHR3 CFHR1 CFH CFB
3 cell surface GO:0009986 9.56 TLR4 THBD CD46 C3
4 extracellular space GO:0005615 9.5 THBD CFI CFHR3 CFHR1 CFH CFB
5 blood microparticle GO:0072562 9.02 CFHR3 CFHR1 CFH CFB C3

Biological processes related to Enterocolitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.8 POLA1 CFI CFH CD46
2 immune system process GO:0002376 9.8 TLR4 NLRC4 CFI CFH CFB CD46
3 innate immune response GO:0045087 9.7 TLR4 NLRC4 CFI CFH CFB CD46
4 complement activation GO:0006956 9.62 CFHR1 CFH CFB C3
5 complement activation, classical pathway GO:0006958 9.61 CFI CD46 C3
6 activation of innate immune response GO:0002218 9.48 TLR4 NLRC4
7 positive regulation of interleukin-10 production GO:0032733 9.46 TLR4 CD46
8 cytolysis by host of symbiont cells GO:0051838 9.4 CFHR5 CFHR1
9 interleukin-1 beta secretion GO:0050702 9.37 TLR4 NLRC4
10 complement activation, alternative pathway GO:0006957 9.26 CFHR5 CFH CFB C3
11 regulation of complement activation GO:0030449 9.17 CFI CFHR5 CFHR1 CFH CFB CD46

Molecular functions related to Enterocolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 TLR4 NLRC4 CFHR5 CFHR1 CFH
2 protein binding GO:0005515 9.4 TLR4 THBD POLA1 NLRC4 CFI CFHR5
3 signaling receptor activity GO:0038023 9.13 TLR4 THBD CD46

Sources for Enterocolitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....